Anti-periodontitis drug and preparation method thereof
By using amino-modified mesoporous silica nanoparticles loaded berberine in anti-perioditis drugs, the cleavage and release mechanism of MMP8 sensitive polypeptides was used to solve the problems of uneven drug loading and limited loading, achieving efficient Drug delivery and periodontal tissue regeneration.
Patent Information
- Application Number
- CN202211531616.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-01
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2042-12-01
AI Technical Summary
Existing anti-perioditis drugs are difficult to evenly load berberine into a temperature-sensitive hydrogel, and the loading volume is limited, affecting its specific delivery.
Amino-modified mesoporous silica nanoparticles are used to connect bovine serum proteins through MMP8-sensitive polypeptides, and berberine is encapsulated in a mesoporous structure to form an MMP-8-specific drug-loading system. The MMP8-sensitive polypeptide is used to cleave and release berberine. .
The efficient loading and specific delivery of berberine in temperature-sensitive hydrogels is achieved, the drug release efficiency and therapeutic effect are improved, and the regeneration ability and inflammatory response of periodontal tissue are significantly improved.
Smart Images

Figure CN115813922B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of anti-periodontitis drugs, and in particular to an anti-periodontitis drug and a preparation method thereof. Background Art
[0002] Periodontitis is one of the main oral diseases. It is a relatively common chronic inflammatory disease in my country and around the world, with a high incidence rate. The clinical manifestations of the disease include gingival bleeding, periodontal pocket formation, loose teeth displacement, and even changes in pronunciation and function. At the same time, periodontitis is also related to a variety of other systemic diseases. It is an inflammatory disease of ecological imbalance that has adverse effects on systemic health.
[0003] Thermosensitive hydrogels are three-dimensional networks of cross-linked hydrophilic polymer chains. Due to their unique structure, thermosensitive hydrogels can absorb large amounts of water or biological fluids while maintaining their integrity. The thermosensitive hydrogels contain a high water content and can also exhibit good biocompatibility and the ability to encapsulate hydrophilic agents in the treatment area. Compared with traditional subcutaneous implantable thermosensitive hydrogels and other local implant materials, in situ formed injectable thermosensitive hydrogel systems have received great attention because of their non-invasiveness and ability to carry therapeutic drugs for site-specific delivery, prolong drug action, improve patient compliance, and reduce systemic toxicity.
[0004] Chitosan (CS) is a polymeric polysaccharide with good biodegradability and biocompatibility. The degradation products of chitosan can support the growth of cells and tissues. Gelatin (GA) is a macromolecular hydrophilic colloid, which is the product of partial hydrolysis of collagen. β-sodium glycerophosphate disodium salt hydrate (GP) is one of the most commonly used cross-linking agents. Berberine (BER) is an isoquinoline alkaloid that can be extracted from a variety of herbs. It has a long history of use in traditional Chinese medicine. In addition to antibacterial effects, berberine also has anti-tumor and anti-inflammatory pharmacological effects. Matrix metalloproteinases-8 (MMP-8) is one of the most important biomarkers of periodontitis, and the peptide sequence sensitive to this enzyme is: Ac-Cys(Trt)-Gly-Pro-Gln-Gly-Ile-Trp-Gly-Gln-Cys(Trt)-OH (MMP8 sensitive peptide, pep). However, berberine is difficult to be evenly loaded into the hydrophilic thermosensitive hydrogel, and the loading amount will also be limited, thus affecting its specific delivery. Summary of the invention
[0005] The object of the present invention is to provide an anti-periodontitis drug and a preparation method thereof, wherein the anti-periodontitis drug has a high specificity for MMP-8 and is conducive to the loading of berberine.
[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0007] The present invention provides an anti-periodontitis drug, comprising a thermosensitive hydrogel and an MMP-8 specific drug-carrying system loaded on the thermosensitive hydrogel;
[0008] The MMP-8 specific drug delivery system comprises amino-modified mesoporous silica nanoparticles and berberine loaded in the mesoporous structure of the amino-modified mesoporous silica nanoparticles;
[0009] The amino-modified mesoporous silica nanoparticles are connected to bovine serum albumin via the MMP8 sensitive polypeptide and the berberine is encapsulated in the mesoporous structure.
[0010] Preferably, the thermosensitive hydrogel comprises chitosan, gelatin and disodium β-glycerophosphate hydrate;
[0011] The mass ratio of chitosan, gelatin and disodium beta-glycerophosphate hydrate salt is (75-85): (0.8-1.2): (180-220).
[0012] Preferably, the mass ratio of the MMP-8 specific drug delivery system to the volume ratio of the thermosensitive hydrogel is (0.8-1.2) g: (80-120) mL.
[0013] The present invention also provides a method for preparing the anti-periodontitis drug described in the above technical solution, comprising the following steps:
[0014] Mixing Fmoc-MMP8 sensitive polypeptide-cooh, polypeptide condensation reagent, N,N-diisopropylethylamine and dimethyl sulfoxide in dichloromethane to obtain a polypeptide solution; Fmoc in the Fmoc-MMP8 sensitive polypeptide-cooh is a protecting group, and cooh is a carboxyl group;
[0015] Mixing amino-modified mesoporous silica nanoparticles and a dimethyl sulfoxide dichloromethane solution to obtain an amino-modified mesoporous silica dispersion;
[0016] The polypeptide solution and the amino-modified mesoporous silica dispersion are mixed and dehydrated and condensed to obtain the MSN-MMP8 sensitive polypeptide-Fmoc;
[0017] The MSN-MMP8 sensitive polypeptide-Fmoc is mixed with a dimethylformamide solution of pyridine, and a deprotection reaction is performed to obtain the MSN-MMP8 sensitive polypeptide;
[0018] Mixing the MSN-MMP8 sensitive polypeptide and the berberine ethanol solution to obtain MSN-MMP8 sensitive polypeptide@BER;
[0019] The MSN-MMP8 sensitive polypeptide @BER, bovine serum albumin, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride, N-hydroxysuccinimide and PBS buffer were mixed to obtain MSN-MMP8 sensitive polypeptide-BSA@BER;
[0020] The MSN-MMP8 sensitive polypeptide-BSA@BER and the thermosensitive hydrogel are mixed to obtain the anti-periodontitis drug.
[0021] Preferably, the usage ratio of the Fmoc-MMP8 sensitive polypeptide-cooh, polypeptide condensation reagent, N,N-diisopropylethylamine and dimethyl sulfoxide dichloromethane solution is (80-120) mg: (80-120) mg: (45-55) μL: (15-25) mL.
[0022] Preferably, the usage ratio of the amino-modified mesoporous silica nanoparticles to the dimethyl sulfoxide dichloromethane solution is (380-420) mg: (35-45) mL.
[0023] Preferably, the mass ratio of berberine in the ethanol solution of the MSN-MMP8 sensitive polypeptide and berberine is (8-12): (6.5-9.5).
[0024] Preferably, the mass ratio of the MSN-MMP8 sensitive polypeptide @BER, bovine serum albumin, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride and N-hydroxysuccinimide is (95-105):(650-700):(300-350):(150-200).
[0025] Preferably, the mass ratio of the MSN-MMP8 sensitive polypeptide-BSA@BER to the volume ratio of the thermosensitive hydrogel is (0.8-1.2) g: (80-120) mL.
[0026] The present invention provides an anti-periodontitis drug, comprising a thermosensitive hydrogel and an MMP-8 specific drug-carrying system loaded on the thermosensitive hydrogel; the MMP-8 specific drug-carrying system comprises amino-modified mesoporous silica nanoparticles and berberine loaded in the mesoporous structure of the amino-modified mesoporous silica nanoparticles; the amino-modified mesoporous silica nanoparticles are connected to bovine serum albumin through an MMP8 sensitive polypeptide and the berberine is encapsulated in the mesoporous structure. The present invention loads the berberine in the mesoporous structure of the amino-modified mesoporous silica nanoparticles, the bovine serum albumin is connected to the mesoporous silica nanoparticles through the MMP8 sensitive polypeptide, and the berberine is encapsulated in the mesoporous structure. When the anti-periodontitis drug encounters MMP8, the MMP8 sensitive polypeptide is cut, so that BSA falls off from the amino-modified mesoporous silica nanoparticles, and the berberine in the mesoporous structure is released. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 This is the SEM image of the MSN prepared in Example 1;
[0028] Figure 2 TEM image of the MSN prepared in Example 1;
[0029] Figure 3 Infrared spectra of MSN (curve a), MSN-NH2 (curve b), MSN-MMP8 sensitive polypeptide-Fmoc (curve c), MSN-MMP8 sensitive polypeptide (curve d) and MSN-MMP8 sensitive polypeptide-BSA@BER (curve e) prepared in Example 1;
[0030] Figure 4 The drug release rate curve of the anti-periodontitis drug described in Example 1 in the buffer solution containing MMP8 and not containing MMP8;
[0031] Figure 5 The in vitro toxicity test results of different experimental groups;
[0032] Figure 6 Results of in vivo experiments for different experimental groups;
[0033] Figure 7 Schematic diagram of periodontal tissue regeneration ability in different experimental groups;
[0034] Figure 8 The bar graphs are for bone volume fraction, tissue mineralization density, interfemoral space, and trabecular thickness in different experimental groups;
[0035] Fig. 9 H&E staining results of different experimental groups;
[0036] Fig.10 Schematic diagram of rat visceral tissues after H&E staining test in different experimental groups. DETAILED DESCRIPTION
[0037] The present invention provides an anti-periodontitis drug, comprising a thermosensitive hydrogel and an MMP-8 specific drug-carrying system loaded on the thermosensitive hydrogel;
[0038] The MMP-8 specific drug delivery system comprises amino-modified mesoporous silica nanoparticles and berberine loaded in the mesoporous structure of the amino-modified mesoporous silica nanoparticles;
[0039] The amino-modified mesoporous silica nanoparticles are connected to bovine serum albumin via the MMP8 sensitive polypeptide and the berberine is encapsulated in the mesoporous structure.
[0040] In the present invention, the thermosensitive hydrogel preferably includes chitosan (CS), gelatin (GA) and disodium β-glycerophosphate hydrate (GP, CAS No.: 154804-51-0); the mass ratio of chitosan, gelatin and disodium β-glycerophosphate hydrate is preferably (75-85): (0.8-1.2): (180-220), more preferably (78-82): (0.9-1.1): (190-210), and most preferably 80:1:200.
[0041] The present invention does not have any special limitation on the source of the thermosensitive hydrogel, and the source familiar to those skilled in the art can be used. In an embodiment of the present invention, the thermosensitive hydrogel is prepared by, and the preparation method of the thermosensitive hydrogel comprises the following steps: mixing chitosan with a hydrochloric acid solution having a volume concentration of 2%, stirring overnight, to obtain a CS hydrogel solution; mixing gelatin (GA) with deionized water, filtering with a 220nm filter membrane, to obtain a GA solution; mixing β-sodium glycerophosphate disodium water and salt (GP) with deionized water, filtering with a 220nm filter membrane, to obtain a GP solution; under stirring, dripping GA solution and GP solution into the CS hydrogel solution, adjusting the pH value to 7 with a 0.1mol / L sodium hydroxide solution, to obtain the thermosensitive hydrogel.
[0042] In the present invention, the mass ratio of the MMP-8 specific drug delivery system to the volume of the thermosensitive hydrogel is preferably 1 g:100 mL.
[0043] In the present invention, the MMP-8 specific drug delivery system preferably comprises amino-modified mesoporous silica nanoparticles and berberine loaded in the mesoporous structure of the amino-modified mesoporous silica nanoparticles. In the present invention, the mass ratio of the amino-modified mesoporous silica nanoparticles to berberine is preferably (4.5-5.5): (0.8-1.2), more preferably (4.8-5.2): (0.9-1.1), and most preferably 5:1.
[0044] The present invention does not have any special limitation on the source of the amino-modified mesoporous silica nanoparticles, and the process well known to those skilled in the art can be used. In an embodiment of the present invention, the amino-modified mesoporous silica nanoparticles are obtained by preparation, and the preparation method of the amino-modified mesoporous silica nanoparticles is as follows: 1.0 g of hexadecyltrimethylammonium bromide (CTAB), 0.28 g of NaOH and 480 mL of deionized water are mixed, maintained at 80°C for 30 minutes, 5.0 g of tetraethoxysilane (TEOS) is added dropwise, stirred evenly until a white precipitate is produced, stirred vigorously for 2 hours for precipitation reaction, centrifuged at 10000 rpm for 10 minutes, the precipitate is collected, and washed with deionized water and methanol for 3 times respectively, and vacuum precipitated. After air drying (0.8 mbar, -50 ° C, 24 h), mesoporous silica nanoparticles (MSN) were obtained; 1.0 g of the MSN and 80 mL of anhydrous toluene (containing 0.75 mL of 3-aminopropyltriethoxysilane (APTS)) were refluxed at 60 ° C for 36 h, then refluxed with 120 mL of methanol, and 7 mL of 37.4% hydrochloric acid solution was added, and the temperature was kept at 80 ° C for 48 h to remove CTAB; ethanol and hydrochloric acid were used to wash and remove APTS, and freeze-dried (0.8 mbar, -50 ° C, 24 h) to obtain MSN-NH2.
[0045] In the present invention, the amino-modified mesoporous silica nanoparticles are connected to bovine serum albumin via an MMP8-sensitive polypeptide and the berberine is encapsulated in the mesoporous structure.
[0046] The present invention also provides a method for preparing the anti-periodontitis drug described in the above technical solution, comprising the following steps:
[0047] Mixing Fmoc-MMP8 sensitive polypeptide-cooh, polypeptide condensation reagent, N,N-diisopropylethylamine and dimethyl sulfoxide in dichloromethane to obtain a polypeptide solution; Fmoc in the Fmoc-MMP8 sensitive polypeptide-cooh is a protecting group, and cooh is a carboxyl group;
[0048] Mixing amino-modified mesoporous silica nanoparticles and a dimethyl sulfoxide dichloromethane solution to obtain an amino-modified mesoporous silica dispersion;
[0049] The polypeptide solution and the amino-modified mesoporous silica dispersion are mixed and dehydrated and condensed to obtain the MSN-MMP8 sensitive polypeptide-Fmoc;
[0050] The MSN-MMP8 sensitive polypeptide-Fmoc is mixed with a dimethylformamide solution of pyridine, and a deprotection reaction is performed to obtain the MSN-MMP8 sensitive polypeptide;
[0051] Mixing the MSN-MMP8 sensitive polypeptide and the berberine ethanol solution to obtain MSN-MMP8 sensitive polypeptide@BER;
[0052] The MSN-MMP8 sensitive polypeptide @BER, bovine serum albumin, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride, N-hydroxysuccinimide and PBS buffer were mixed to obtain MSN-MMP8 sensitive polypeptide-BSA@BER;
[0053] The MSN-MMP8 sensitive polypeptide-BSA@BER and the thermosensitive hydrogel are mixed to obtain the anti-periodontitis drug.
[0054] In the present invention, unless otherwise specified, all preparation raw materials are commercially available products well known to those skilled in the art.
[0055] The invention mixes a dichloromethane solution of Fmoc-MMP8 sensitive polypeptide-cooh, a polypeptide condensation reagent, N,N-diisopropylethylamine and dimethyl sulfoxide to obtain a polypeptide solution; Fmoc in the Fmoc-MMP8 sensitive polypeptide-cooh is a protective group, and cooh is a carboxyl group.
[0056] In the present invention, the polypeptide condensation agent is preferably HATU.
[0057] In the present invention, the volume percentage of dimethyl sulfoxide in the dichloromethane solution of dimethyl sulfoxide is preferably 8-12%, more preferably 9-11%, and most preferably 10%.
[0058] In the present invention, the usage ratio of the Fmoc-MMP8 sensitive polypeptide-cooh, polypeptide condensation reagent and N,N-diisopropylethylamine is preferably (80-120) mg: (80-120) mg: (45-55) μL, more preferably (90-110) mg: (90-110) mg: (48-52) μL, and most preferably 100 mg: 100 mg: 50 μL.
[0059] In the present invention, the usage ratio of the Fmoc-MMP8 sensitive polypeptide-cooh and dimethyl sulfoxide is preferably (80-120) mg: (0.15-0.25) mL, more preferably (90-110) mg: (0.18-0.22) mL, and most preferably 100 mg: 0.2 mL.
[0060] After the mixing is completed, the present invention also preferably includes stirring at room temperature; the present invention has no special limitation on the stirring, and the stirring can be carried out using a process well known to those skilled in the art. In an embodiment of the present invention, the stirring time is specifically 30 minutes.
[0061] The preparation method of the present invention further comprises mixing the amino-modified mesoporous silica nanoparticles and a dichloromethane solution of dimethyl sulfoxide to obtain an amino-modified mesoporous silica dispersion.
[0062] In the present invention, the volume concentration of the dimethyl sulfoxide dichloromethane solution is preferably 10%.
[0063] In the present invention, the usage ratio of the amino-modified mesoporous silica nanoparticles to the dimethyl sulfoxide dichloromethane solution is preferably (350-450) mg: (35-45) mL, more preferably (380-420) mg: (38-42) mL, and most preferably 400 mg: 40 mL.
[0064] The present invention does not have any special limitation on the mixing process, and the mixing process may be carried out using a process well known to those skilled in the art.
[0065] After obtaining the polypeptide solution and the amino-modified mesoporous silica dispersion, the present invention mixes the polypeptide solution and the amino-modified mesoporous silica dispersion and performs dehydration condensation to obtain MSN-polypeptide-Fmoc.
[0066] In the present invention, the mass ratio of Fmoc-MMP8 sensitive polypeptide-cooh in the polypeptide solution and amino-modified mesoporous silica in the amino-modified mesoporous silica dispersion is preferably (0.8-1.2):(3.5-4.5), more preferably (0.9-1.1):(3.8-4.2), and most preferably 1:4.
[0067] The present invention has no special limitation on the mixing process, and a process well known to those skilled in the art can be used to fully react the amino groups in the amino-modified mesoporous silica with the carboxyl groups in the polypeptide solution. In an embodiment of the present invention, the mixing temperature is room temperature and the mixing time is 36 hours.
[0068] After the mixing is completed, the present invention further preferably includes centrifugation. The present invention has no special limitation on the centrifugation process, and the solid-liquid separation can be achieved by using a process well known to those skilled in the art. In an embodiment of the present invention, the centrifugation speed is 8000 rpm and the time is 10 min.
[0069] After obtaining the MSN-MMP8 sensitive polypeptide-Fmoc, the present invention mixes the MSN-MMP8 sensitive polypeptide-Fmoc with a dimethylformamide solution of pyridine, and performs a deprotection reaction to obtain the MSN-MMP8 sensitive polypeptide.
[0070] Before mixing, the present invention preferably washes the MSN-MMP8 sensitive polypeptide-Fmoc, and the washing is preferably carried out 3 times with a dichloromethane solution having a volume percentage of 10% dimethyl sulfoxide.
[0071] In the present invention, the volume concentration of pyridine in the dimethylformamide solution of pyridine is preferably 15 to 25%, more preferably 18 to 22%, and most preferably 20%.
[0072] The present invention does not have any special restrictions on the amount of the pyridine dimethylformamide solution and the deprotection reaction time. The amount and deprotection reaction time known to those skilled in the art can be used to ensure that the protecting group Fmoc is completely removed.
[0073] After the deprotection reaction is completed, the present invention also preferably includes repeating centrifugation, washing and drying six times in sequence; the speed of the centrifugation is preferably 8000 rpm, and the time is preferably 10 min; the washing is preferably carried out with deionized water.
[0074] After repeating the above centrifugation, washing and drying for 6 times, the present invention further preferably includes vacuum drying, wherein the pressure of the vacuum drying is preferably 0.8 mbar, the temperature is preferably -50°C, and the time is preferably 24 hours.
[0075] After obtaining the MSN-MMP8 sensitive polypeptide, the present invention mixes the MSN-MMP8 sensitive polypeptide with an ethanol solution of berberine to obtain MSN-polypeptide@BER.
[0076] In the present invention, the concentration of the berberine ethanol solution is preferably 0.35-0.45 mg / mL, more preferably 0.38-0.42 mg / mL, and most preferably 0.4 mg / mL.
[0077] In the present invention, the mass ratio of berberine in the ethanol solution of MSN-polypeptide and berberine is preferably (8-12):(6.5-9.5), more preferably (9-11):(7-9), and most preferably 10:8.
[0078] After the mixing is completed, the present invention further preferably includes continuing stirring; the present invention has no special limitation on the process of continuing stirring, and the process well known to those skilled in the art can be used. In an embodiment of the present invention, the temperature of continuing stirring is specifically room temperature, and the time is specifically 48 hours.
[0079] After the continued stirring is completed, the present invention also preferably includes washing with PBS buffer for 3 times.
[0080] After obtaining the MSN-MMP8 sensitive polypeptide @BER, the present invention mixes the MSN-MMP8 sensitive polypeptide @BER, bovine serum albumin, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride, N-hydroxysuccinimide and PBS buffer to obtain MSN-MMP8 sensitive polypeptide-BSA@BER.
[0081] In the present invention, the mass ratio of the MSN-MMP8 sensitive polypeptide @BER, bovine serum albumin, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride and N-hydroxysuccinimide is preferably (95-105):(650-700):(300-350):(150-200), and most preferably 100:666:333:166.
[0082] In the present invention, the dosage ratio of the MSN-MMP8 sensitive polypeptide @BER to PBS buffer is preferably (95-105) mg: (95-105) mL, and most preferably 100 mg: 100 mL.
[0083] After the mixing is completed, the present invention further preferably includes continuing stirring; the present invention has no special limitation on the process of continuing stirring, and the process well known to those skilled in the art can be used. In an embodiment of the present invention, the temperature of continuing stirring is specifically room temperature, and the time is specifically 36 hours.
[0084] After obtaining the MSN-MMP8 sensitive polypeptide-BSA@BER, the present invention mixes the MSN-MMP8 sensitive polypeptide-BSA@BER with a thermosensitive hydrogel to obtain the anti-periodontitis drug.
[0085] In the present invention, the mass ratio of the MSN-MMP8 sensitive polypeptide-BSA@BER to the volume ratio of the thermosensitive hydrogel is preferably (0.8-1.2) g: (80-120) mL, and most preferably 1 g: 100 mL.
[0086] The anti-periodontitis drug and the preparation method thereof provided by the present invention are described in detail below in conjunction with the examples, but they should not be construed as limiting the protection scope of the present invention.
[0087] Example 1
[0088] 1.0 g of hexadecyltrimethylammonium bromide (CTAB), 0.28 g of NaOH and 480 mL of deionized water were mixed, maintained at 80°C for 30 min, and then 5.0 g of tetraethoxysilane (TEOS) was added dropwise, stirred evenly until a white precipitate was produced, stirred vigorously for 2 h for precipitation reaction, centrifuged at 10000 rpm for 10 min, and the precipitate was collected and washed with deionized water and methanol three times respectively, and vacuum dried (0.8 mbar, -50°C, 24 h) to obtain mesoporous silica nanoparticles (MSN);
[0089] 1.0 g of the MSN and 80 mL of anhydrous toluene (containing 0.75 mL of 3-aminopropyltriethoxysilane (APTS)) were refluxed at 60° C. for 36 h, then refluxed with 120 mL of methanol, and 7 mL of a 37.4% hydrochloric acid solution was added, and maintained at 80° C. for 48 h to remove CTAB; ethanol and hydrochloric acid were used to wash and remove APTS, and freeze-dried (0.8 mbar, -50° C., 24 h) to obtain MSN-NH2;
[0090] 100 mg of Fmoc-MMP8 sensitive peptide-cooh, 100 mg of peptide condensation reagent (HATU), 50 μL of N,N-diisopropylethylamine (DIEA) and 20 mL of dichloromethane (DCM) solution (containing 10% by volume of dimethyl sulfoxide (DMSO)) were mixed and stirred at room temperature for 30 min to obtain a peptide solution;
[0091] Mix 400 mg of the MSN-NH2 and 40 mL of a dichloromethane (DCM) solution (containing 10% by volume of dimethyl sulfoxide (DMSO)) to obtain a MSN-NH2 dispersion;
[0092] The polypeptide solution and the MSN-NH2 dispersion were mixed and reacted for 36 hours, and then centrifuged (8000 rpm, 10 min) to obtain the MSN-MMP8 sensitive polypeptide-Fmoc;
[0093] The MSN-MMP8 sensitive polypeptide-Fmoc was washed three times with a dimethyl sulfoxide dichloromethane solution with a volume percentage of 10%, and incubated in 30 mL of a 20% pyridine dimethylformamide solution for 20 min to remove the protective group Fmoc, and centrifugation (8000 rpm, 10 min), deionized water washing and drying were repeated six times, and vacuum dried (0.8 mbar, -50°C, 24 h) to obtain the MSN-MMP8 sensitive polypeptide;
[0094] 100 mg of the MSN-MMP8 sensitive polypeptide and 200 mL of 0.4 mg / mL berberine ethanol solution were mixed, stirred at room temperature for 48 h, and washed three times with PBS buffer solution to obtain MSN-MMP8 sensitive polypeptide @BER;
[0095] 100 mg of the MSN-MMP8 sensitive polypeptide @ BER, 666 mg of bovine serum albumin (BSA), 333 mg of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), 166 mg of N-hydroxysuccinimide and 100 mL of PBS buffer were mixed and stirred at room temperature for 36 hours to obtain MSN-MMP8 sensitive polypeptide-BSA @ BER;
[0096] 2 g of chitosan (CS) and 100 mL of 2% HCl solution were mixed to obtain a CS solution;
[0097] 0.5 g of gelatin (GA) and 100 mL of deionized water were mixed and filtered through a 220 nm filter to obtain a GA solution (concentration of 0.5% (w / v));
[0098] After mixing 56 g of β-glycerophosphate disodium water and salt (GP) with 100 mL of deionized water, the mixture was filtered through a 220 nm filter membrane to obtain a GP solution (concentration of 56% (w / v));
[0099] Under stirring, 1 mL of GA solution and 0.125 mL of GP solution were dropped into 5 mL of the CS solution, and the pH value was adjusted to 7 with 0.1 mol / L sodium hydroxide solution to obtain a CS / GP / GA thermosensitive hydrogel solution;
[0100] 1 g of the MSN-MMP8 sensitive polypeptide-BSA@BER and 100 mL of the CS / GP / GA thermosensitive hydrogel solution were mixed to obtain the anti-periodontitis drug (the dosage ratio of MSN-MMP8 sensitive polypeptide-BSA@BER to CS / GP / GA thermosensitive hydrogel was 1 g:100 mL (w / v), recorded as thermosensitive hydrogel+MSN@ber).
[0101] Test Case
[0102] The MSN prepared in Example 1 was subjected to SEM test. The test results are as follows: Figure 1 As shown, the MSN prepared in Example 1 was subjected to TEM test, and the test results are shown in Figure 2 As shown by Figure 1 and 2 It can be seen that mesoporous silica spheres with regular size and shape were formed;
[0103] The MSN (curve a), MSN-NH2 (curve b), MSN-MMP8 sensitive polypeptide-Fmoc (curve c), MSN-MMP8 sensitive polypeptide (curve d) and MSN-MMP8 sensitive polypeptide-BSA@BER (curve e) prepared in Example 1 were subjected to infrared spectroscopy tests. The test results are shown in FIG. Figure 3 As shown by Figure 3 From the curve a in the figure, we can see that MSN is at 1092cm -1 and 960cm -1 The strong absorption signal is mainly due to the asymmetric stretching of Si-O-Si bridge bond and the skeleton vibration of CO bond stretching. Figure 3 From the curve b in Figure 1, we can see that compared with MSN, MSNs-NH2 has a higher -1 There is signal absorption, which is attributed to the stretching vibration of amide and -NH2 bending, which indicates that the NH2 group is coupled to MSN. Figure 3 As can be seen from the curve c in FIG, the MSN-MMP8 sensitive peptide-Fmoc has a peak at 1659 cm -1 and 1546cm -1 The absorption peak is observed at , which is caused by the vibration of the peptide chain caused by stretching; Figure 3 From curve d in the figure, we can see that after removing Fmoc, the absorption peak of the protecting group is at 1659 cm -1 and 1546cm -1 The peptide chains shifted slightly to 1655 cm -1 and 1542cm -1 ;Depend on Figure 3 From the curve e in the figure, we can see that at 2960cm -1 A new peak was observed at 1658 cm-1, which is due to the skeleton vibration of the CH bond in the BSA molecule. -1 and 1542cm -1 The absorption peak at is significantly increased, which is caused by the stretching vibration of the peptide chain BSA.
[0104] Drug release rate test:
[0105] 1mL of the anti-periodontitis drug prepared in Example 1 was soaked in 5mL of PBS buffer with a concentration of 0.01mol / L. The PBS buffer after soaking was taken at 1d, 2d, 3d, 4d, 5d, 6d, 7d, 8d, 10d, 12d, 14d and 16d, and a new PBS was replaced to detect the concentration of berberine in the PBS buffer after soaking. The concentration of berberine was determined by ultraviolet spectrophotometry, and the detection wavelength was 345nm. The calculation formula is: A=0.015744C+0.192 (A: absorbance value, C: berberine concentration). The plate used for the test was stored in a 37°C, 5% CO2 incubator with a rotation speed of (60rpm). According to the measured concentration, the release ratio of berberine in the thermosensitive hydrogel was calculated. There were two groups in the experiment, one of which was added with 1% (w / v) MMP8 in PBS at 2d.
[0106] The experimental results are as follows Figure 4 As shown by Figure 4 It can be seen that, for the thermosensitive hydrogel without adding MMP8, the release rate weight loss is maintained at a lower concentration, and the overall release rate of the drug is only about 25% at 16 days. After adding MMP8 at 2 days, the berberine release rate of the system is rapidly improved, and the release rate of ber reaches about 65% at 3 days and about 92% at 16 days, and then the release rate gradually stabilizes. This shows that when MMP8 is present in the environment, the MMP8-specific polypeptide can be cut to release ber in MSN. When MMP8 is not contained in the environment, the MMP8-specific polypeptide cannot be cut, and ber in MSN cannot be released, and the release rate of ber is very low. This shows that the anti-periodontitis drug described in the present invention has a high degree of MMP8 specificity, can achieve specific treatment, and has good release efficiency and a long effective release time.
[0107] In vitro and in vivo cytotoxicity tests of drug delivery systems:
[0108] In vitro experiment: The cytotoxicity was detected using the MTT method. Four groups were set up in the experiment: blank control group, thermosensitive hydrogel group, thermosensitive hydrogel group with MSN, and the anti-periodontitis drug prepared in Example 1. The experiment was carried out in a six-well transfer chamber, and the bottom of each chamber was equipped with a polycarbonate membrane (pore size 0.4μm). 1mL of each component pre-gel was added to the upper chamber and stored at 37°C to form a gel. The third-generation rat bone marrow mesenchymal stem cells (BMSCs) were inoculated in the lower well, and 2×10 5Cells / well were inoculated. After 24 hours, the upper well was removed, and 200uL of 5mg / mL MTT kit was added to each well. After incubation for 4h, formazan crystals were observed at the bottom of each well. The supernatant was then removed. The crystals were dissolved in DMSO, and then the dissolved solution was transferred to a 96-well plate and observed at 490nm using an ELISA reader. The experiment was repeated three times. The test results are shown in Figure 5 As shown by Figure 5 It can be seen that there is no significant difference in the proliferation of BMSCs in the four experimental groups compared with the control group. The results show that the anti-periodontitis drug of the present invention does not cause cytotoxicity or any side effects in vitro;
[0109] In vivo experiment: 20 6-week-old SD rats were randomly divided into 4 groups, 5 rats in each group, and divided into blank control group, thermosensitive hydrogel group, thermosensitive hydrogel + MSN group, and anti-periodontitis drug group prepared in Example 1. Rats were anesthetized with isoflurane, and 4-0 surgical sutures were used to fix the sutures around the second molars of the maxilla of the rats. Subsequently, the midpoints of the buccal and palatal sides of the second molar were injected, 25uL PBS in the control group, and 25mL pre-gels of other components were injected 5 times every 3 days in the next 2 weeks. Two weeks after implantation, the rats were euthanized by overdose of CO2 inhalation, and the maxillary tissues, heart, liver, spleen, lungs, and kidneys of the rats were removed. The tissues were fixed with 4% PFA (2 days), and the maxillary tissues were observed using microCT scanning with scanning parameters (114mA, 70kvp, exposure time 300ms). Observe the 3D images and imaging images of the rat maxilla, and analyze the osteogenic parameters. After the scan, the maxillary tissue was demineralized, and histopathological analysis (HE staining) was performed to observe the inflammation; the test results are as follows Figure 6 As shown in the figure, a is the vertical distance between the cementoenamel junction (CEJ) and the alveolar bone crest (ABC), which represents the degree of alveolar bone loss, and b is a bar graph; Figure 6 It can be seen that the distance of the untreated blank control group is the longest, while the distance of the anti-periodontitis drug group prepared in Example 1 is the shortest, with significant differences, indicating that the anti-periodontitis drug prepared in Example 1 of the present invention has a positive effect on alveolar bone regeneration;
[0110] Using microCT for analysis, Figure 7 Schematic diagram of periodontal tissue regeneration ability of blank control group, thermosensitive hydrogel group, thermosensitive hydrogel + MSN group, and anti-periodontitis drug group prepared in Example 1 (a is a physical picture of maxillary tissues in different experimental groups (the white circle represents alveolar bone), and b is a 3D picture of maxillary tissues in different experimental groups); Figure 7It can be seen that the periodontal tissue regeneration ability of the anti-periodontitis drug group prepared in Example 1 is consistent with the adjustment angle, and the anti-periodontitis drug prepared in the present invention has a positive effect on alveolar bone regeneration. The alveolar bone regeneration effect of the experimental group using the anti-periodontitis drug prepared in Example 1 is good;
[0111] The specific data of the microCT were analyzed, and the analysis results were as follows: Figure 8 As shown, Figure 8 The bar graphs are the bone volume fraction, tissue mineralization density, interfemoral space and trabecular thickness of different experimental groups; Figure 8 It can be seen that compared with the blank control group, the bone volume fraction (BV / TV) of the experimental group using the anti-periodontitis drug prepared in Example 1 increased by nearly 250%, the tissue mineralization density (TMD) increased by nearly 160%, the bone gap (Tb.Sp) decreased by nearly 50%, and the trabecular thickness (Tb.Th) increased by nearly 100%, indicating that the anti-periodontitis drug of the present invention has a positive effect on alveolar regeneration;
[0112] To further confirm the above results, we performed H&E staining ( Fig. 9 ) to evaluate the inflammatory status and periodontal tissue regeneration. In the blank control group, the interdental papillae disappeared and the alveolar bone was absorbed, resulting in a significant decrease in the vertical distance between the cementoenamel junction (CEJ) and the alveolar bone ridge (ABC). A large number of neutrophils, lymphocytes and plasma cells were seen, and the periodontal fibers were disordered. Compared with the control group, the inflammation in the thermosensitive hydrogel group and the thermosensitive hydrogel + MSN group was alleviated, while the inflammatory response of the experimental group using the anti-periodontitis drug prepared in Example 1 was greatly improved, and the interdental papillae showed a trend of appearing. The HE results show that the anti-periodontitis drug prepared in Example 1 has a good effect in eliminating inflammation and promoting alveolar bone regeneration.
[0113] One rat was randomly selected from each group after the H&E staining test, and the internal organs were removed to make tissue sections for HE staining observation. The results were as follows: Fig.10 As shown by Fig.10 It can be seen that the visceral tissue structures of rats in each group were normal and unchanged, indicating that the anti-periodontitis drug of the present invention is not toxic to mammals and has good biocompatibility in animals.
[0114] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. An anti-periodontitis drug, characterized in that: It comprises a thermosensitive hydrogel and an MMP-8 specific drug-carrying system loaded on the thermosensitive hydrogel; The MMP-8 specific drug delivery system comprises amino-modified mesoporous silica nanoparticles and berberine loaded in the mesoporous structure of the amino-modified mesoporous silica nanoparticles; The amino-modified mesoporous silica nanoparticles are connected to bovine serum albumin via the MMP8 sensitive polypeptide and the berberine is encapsulated in the mesoporous structure; The sequence of the MMP8 sensitive polypeptide is: Ac-Cys(Trt)-Gly-Pro-Gln-Gly-Ile-Trp-Gly-Gln-Cys(Trt)-OH.
2. The anti-periodontitis drug according to claim 1, characterized in that: The thermosensitive hydrogel comprises chitosan, gelatin and disodium β-glycerophosphate hydrate; The mass ratio of chitosan, gelatin and disodium β-glycerophosphate hydrate is (75-85): (0.8-1.2): (180-220).
3. The anti-periodontitis drug according to claim 1 or 2, characterized in that: The mass ratio of the MMP-8 specific drug delivery system to the volume ratio of the thermosensitive hydrogel is (0.8-1.2) g: (80-120) mL.
4. The method for preparing the anti-periodontitis drug according to any one of claims 1 to 3, characterized in that: The following steps are involved: Mixing Fmoc-MMP8 sensitive polypeptide-cooh, polypeptide condensation reagent, N,N-diisopropylethylamine and dimethyl sulfoxide in dichloromethane to obtain a polypeptide solution; Fmoc in the Fmoc-MMP8 sensitive polypeptide-cooh is a protecting group, and cooh is a carboxyl group; Mixing amino-modified mesoporous silica nanoparticles and a dimethyl sulfoxide dichloromethane solution to obtain an amino-modified mesoporous silica dispersion; The polypeptide solution and the amino-modified mesoporous silica dispersion are mixed and dehydrated and condensed to obtain the MSN-MMP8 sensitive polypeptide-Fmoc; The MSN-MMP8 sensitive polypeptide-Fmoc is mixed with a dimethylformamide solution of pyridine, and a deprotection reaction is performed to obtain the MSN-MMP8 sensitive polypeptide; Mixing the MSN-MMP8 sensitive polypeptide and the berberine ethanol solution to obtain MSN-MMP8 sensitive polypeptide@BER; The MSN-MMP8 sensitive polypeptide @BER, bovine serum albumin, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride, N-hydroxysuccinimide and PBS buffer were mixed to obtain MSN-MMP8 sensitive polypeptide-BSA@BER; The MSN-MMP8 sensitive polypeptide-BSA@BER and the thermosensitive hydrogel are mixed to obtain the anti-periodontitis drug.
5. The preparation method according to claim 4, characterized in that: The dosage ratio of the Fmoc-MMP8 sensitive polypeptide-cooh, polypeptide condensation reagent, N,N-diisopropylethylamine and dimethyl sulfoxide dichloromethane solution is (80-120) mg: (80-120) mg: (45-55) μL: (15-25) mL.
6. The preparation method according to claim 5, characterized in that: The dosage ratio of the amino-modified mesoporous silica nanoparticles to the dimethyl sulfoxide dichloromethane solution is (380-420) mg: (35-45) mL.
7. The preparation method according to claim 4, characterized in that: The mass ratio of berberine in the ethanol solution of the MSN-MMP8 sensitive polypeptide and berberine is (8-12): (6.5-9.5).
8. The preparation method according to claim 4, characterized in that: The mass ratio of the MSN-MMP8 sensitive polypeptide @BER, bovine serum albumin, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride and N-hydroxysuccinimide is (95-105): (650-700): (300-350): (150-200).
9. The preparation method according to claim 4, characterized in that: The mass ratio of the MSN-MMP8 sensitive polypeptide-BSA@BER to the volume ratio of the thermosensitive hydrogel is (0.8~1.2) g: (80~120) mL.
